ImmuneOnco Biopharma

Executive Summary

ImmuneOnco Biopharma is a clinical-stage Chinese biopharmaceutical company pioneering novel therapies targeting the innate immune system, with a focus on the phagocytosis checkpoint pathway. Its lead asset, IMM01, is a first-in-class CD47-targeting fusion protein undergoing clinical evaluation for hematologic malignancies and solid tumors. The company leverages its expertise to develop biologics for cancer and autoimmune diseases, aiming to address high unmet medical needs. With a robust pipeline and a differentiated mechanism of action, ImmuneOnco is positioned to make significant contributions to immuno-oncology. The company's progress in Phase 2 trials and its potential to expand into autoimmune indications underscore its strategic importance in the competitive CD47 space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for IMM01 in hematologic malignancies25% success
• Q2 2026IND filing or early data for next-generation innate immune checkpoint inhibitor40% success
• Q3 2026Potential partnership or licensing deal for IMM01 in Greater China or globally30% success